News
Semaglutide, the active ingredient in popular drugs Ozempic and Wegovy, isn’t without its risks. A recent study has found ...
Ready to transform your body? It's possible with this program's personalized care, telehealth consultations, and semaglutide ...
Disparities in prescribing semaglutide and tirzepatide for obesity reveal social factors affecting access and highlight the ...
Compounding pharmacies will no longer be allowed to create semaglutide injections, a generic and cheaper version of Ozempic and Wegovy. This comes after a judge rejected a bid by these pharmacies to ...
Recently, the FDA announced the removal of certain compounded GLP1 ingredients from its drug shortage list. These ingredients ...
Click in for more news from The Hill{beacon} Health Care Health Care The Big Story Novo Nordisk partners with telehealth ...
Novo Nordisk appears to be letting compounded GLP-1 bygones be bygones—at least, in one respect. | Novo Nordisk appears to be ...
A federal judge rejected a bid by compounding pharmacies to continue selling versions of weight-loss drug Wegovy and diabetes ...
All these drugs are very effective and they’ve become a game changer for people who need to lose weight. Get on the drug, eat ...
(Reuters) -Danish drugmaker Novo Nordisk has partnered with Hims & Hers Health's to sell its popular weight loss drug through ...
Novo Nordisk scored a legal win against compounders of its blockbuster GLP-1 drugs. But it may not end the copycats.
A judge denied compounders' request to keep making off-brand Wegovy and Ozempic after the FDA removed semaglutide from its shortage list.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results